Click on image to view larger version.

Figure 4 Logit of the Primary End Point Stratified by Continuous Baseline LDL-C

When LDL-C was treated as a continuous variable, the benefit of atorvastatin 80 mg over pravastatin 40 mg for the prevention of the primary end point was not present at baseline levels of LDL-C <66 mg/dl. A significant multivariate-adjusted interaction between treatment and baseline LDL-C was observed (adjusted interaction p = 0.02). Abbreviations as in Figure 1.